To move Epitalon from experimental to evidence-based, several developments are essential: Randomized, double-blind, placebo-controlled clinical trials, ideally targeting specific endpoints (sleep, immune aging, telomere attrition) Toxicology and long-term safety studies, including exploration of stereoisomer effects and off-target consequences Validated delivery systems (e.g., dendrimer-conjugates, transdermal patches) that make real-world use feasible Pharmacodynamic biomarkers, to identify responders and track efficacy objectively over time Epitalon is not snake oil, but its also not a magic bullet
These are the current GLP-1 costs for the cheapest options
Inflammatory profiling of patients with familial amyloid polyneuropathy
Accessed August 15, 2023
However, long-acting GCG receptor (GCGR) agonists have also been shown to dose-dependently stimulate insulin secretion and enhance energy expenditure and fatty acid oxidation, leading to substantial weight loss in rodents [4, 5]